Bell's Palsy Following SARS-CoV-2 Vaccines: A Systematic Review and Meta-**Analysis**

Running title: Bell's Palsy Following SARS-CoV-2 Vaccines

Ali Rafati^{1†}, MD, MPH; Yeganeh Pasebani^{1†}, MD; Melika Jameie², MD; Yuchen Yang³; Mana Jameie⁴, MD, MPH; Saba Ilkhani⁵, MD, MPH; Mobina Amanollahi², MD; Delaram Sakhaei⁶, MD; Mehran Rahimlou^{7*}, PhD; Amir Kheradmand^{8*}, MD.

- 1. School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
- 2. Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
- 3. Department of Neurology and Otolaryngology-Head & Neck Surgery, Johns Hopkins University, School of Medicine, Baltimore, MD, USA.
- 4. Cardiovascular Diseases Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
- 5. Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- 6. School of Medicine, Sari branch, Islamic Azad University, Sari, Iran.
- 7. Department of Nutrition, School of Medicine, Zanjan University of Medical Sciences, Zanjan,
- 8. Departments of Neurology, Neuroscience, Otolaryngology-Head & Neck Surgery, and Laboratory for Computational Sensing and Robotics (LCSR), Johns Hopkins University, School of Medicine, Baltimore, MD, USA.

*Corresponding authors:

Amir Kheradmand, M.D.

o The Johns Hopkins Hospital, Department of Neurology, Vestibular and Ocular motor (VOR) Laboratory, Path 2-210, 600 N. Wolfe Street, Baltimore, MD, 21287, USA. Email: akherad@jhu.edu, Phone: +1-410-955-3319. Fax: +1-410-614-1746.

Mehran Rahimlou, PhD

Department of Nutrition, School of Medicine, Zanjan University of Medical Sciences, Phone: +98-914-742-547. Fax: +98-243-377-9244. Rahimlum@gmail.com

[†]These two authors contributed equally.

Abstract

Background and Objective

Bell's palsy (BP) has been considered as a serious adverse event following the SARS-CoV-2 vaccination. Many studies have reported BP following vaccination, although neither a causative relationship nor a prevalence of the condition higher than the general population has been established. The outcomes of interest were to compare BP incidence among (a) SARS-CoV-2 vaccine recipients, (b) nonrecipients in the placebo or unvaccinated cohorts, (c) different types of SARS-CoV-2 vaccines, and (d) SARS-CoV-2 infected vs. SARS-CoV-2 vaccinated individuals.

Methods

We performed a systematic search through MEDLINE (via PubMed), Web of Science, Scopus, Cochrane library, and Google Scholar from the inception to August 15, 2022. We included articles reporting individuals receiving any SARS-CoV-2 vaccine in whom BP had occurred. Studies reporting facial paralysis due to etiologies other than BP were excluded. Random- and fixed-effects meta-analyses using the Mantel-Haenszel method were conducted for the quantitative synthesis. Newcastle-Ottawa scale (NOS) was used to assess the quality. The study was conducted in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline, and the protocol was registered with PROSPERO (CRD42022313299). Analyses were carried out using the R, version 4.2.1 (R package 'meta' version 5.2-0).

Results

Fifty studies were included, of which 17 entered the quantitative synthesis. First, pooling four phase-3 randomized controlled trials (RCT) indicated BP occurrence was significantly higher in SARS-CoV-2 vaccines (77, 525 doses) compared to placebo (66, 682 doses) (OR = 3.00, 95% CI = 1.10 - 8.18, $I^2 = 0\%$). Second, pooling nine observational studies of mRNA SARS-CoV-2 vaccine doses (13, 518,026) and matched unvaccinated individuals (13, 510,701) revealed no significant increase in the odds of BP in the vaccinated group compared to the unvaccinated group (OR: 0.70 (95% CI 0.42-1.16), $I^2=94\%$). The third meta-analysis suggested that post-vaccination BP among first dose Pfizer/BioNTech recipients (22,760,698) did not significantly differ from that in first dose Oxford/AstraZeneca recipients (22,978,880) (OR = 0.97, 95% CI = 0.82 - 1.15, $I^2 = 0\%$). According to the fourth meta-analysis, BP was significantly more commonly reported after SARS-CoV-2 infection (2,641,398) than after SARS-CoV-2 vaccinations (36,988,718) (RR = 4.03, 95% CI = 1.78 - 9.12, $I^2 = 96\%$).

Conclusion

Our meta-analysis suggests a higher incidence of BP among vaccinated vs. placebo groups. BP occurrence did not significantly differ between Pfizer/BioNTech and Oxford/AstraZeneca vaccines. SARS-CoV-2 infection posed a significantly greater risk for BP than SARS-CoV-2 vaccines.

Keywords: Bell Palsy, Facial Paralysis, COVID-19 Vaccines, COVID-19, Systematic Review, Meta-Analysis

Introduction

Bell's palsy (BP), also known as idiopathic facial nerve palsy, is the most prevalent cause of acute spontaneous peripheral facial paralysis, with a reported annual incidence rate of 15-30 cases per 100,000 population (1, 2). Although the exact etiology of BP is unclear, viral infections (such as herpes simplex virus (HSV)), ischemia, and inflammation are some of the suggested underlying mechanisms (3). Notably, BP is also reported following SARS-CoV-2 infection (4). Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a contagious respiratory syndrome with a wide range of manifestations from asymptomatic and mild infection to hospitalization and death (5), as well as a wide variety of neurological manifestations (6).

By August 19, 2022, a total of 591,683,619 patients with COVID-19 and 6,443,306 deaths had been reported worldwide (5). As of August 16, 2022, 12,409,086,286 doses of SARS-CoV-2 vaccines have been administrated worldwide (5), resulting in a dramatic decrease in COVID-19-associated hospitalizations and deaths (7-9). The vaccines are safe and effective, as evinced by several clinical trials and confirmed by the national and international public health agencies (10-13). Nevertheless, apart from nonserious complications such as local reactions (14), other adverse events have also been reported affecting the liver (15), kidneys (16), cardiovascular system (17), and central nervous system (CNS) (18). Headaches (19, 20), Guillain-Barre syndrome (GBS) (21), cerebral venous sinus thrombosis (22, 23), and transverse myelitis (24, 25) are the most frequently reported neurological adverse events following SARS-CoV-2 vaccination. Many studies have also reported BP following vaccination, although neither a causative relationship nor a prevalence of the condition higher than the general population has been established.

The diagnosis of BP is mainly based on physical examination indicative of a sudden onset paralysis or paresis of muscle groups on one side of the face in the absence of CNS disease and after excluding the other causes of acute peripheral palsy (2) and the management includes early treatment with oral corticosteroids and eye care to prevent corneal injury (26). The benefits of antiviral therapy remain unproven (26). The majority of patients with BP resolve after a few months. However, the extent of nerve degeneration, age, and hypertension may predict poor outcomes (27).

Since vaccination has been conducted globally, identifying the related short and long-term adverse events is of great significance. Reviewing the literature indicates several studies reporting BP occurrence following SARS-CoV-2 vaccination (28, 29). The first documented case was a 36-year-old woman with a previous history of BP who developed facial palsy two days after receiving the first dose of the Sinovac vaccine (30). Currently, given the differences in the design and other characteristics of the studies reporting BP after vaccination, such as the differences in the time interval between the vaccine and the event, types of vaccine, diagnostic methods, the lack of a control group in many studies, it is impossible to conclude

whether there is a causal association between BP and SARS-CoV-2 vaccination or the reported cases are primarily coincidental. To address this issue, here we conducted a systematic review and meta-analysis of the studies reporting BP following SARS-CoV-2 vaccines to answer whether SARS-CoV-2 vaccination increases the incidence of BP compared to (i) unvaccinated or (ii) placebo-vaccinated individuals (III) whether BP occurrence is different among various types of SARS-CoV-2 vaccines, or (iv) whether it is different among SARS-CoV-2 infected vs. SARS-CoV-2 vaccinated individuals.

Methods

Objectives

We sought to investigate BP incidence by measuring the pooled effect estimates in the subsequent sets of comparisons:

- All phase-3 RCT-derived data on vaccine vs. saline placebo recipients.
- mRNA SARS-CoV-2 vaccines vs. unvaccinated participants in observational studies.
- Pfizer/BioNTech vs. Oxford/AstraZeneca SARS-CoV-2 vaccines.
- SARS-CoV-2 infections vs. SARS-CoV-2 vaccines.

Study design and search strategy

This study was conducted in line with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (31); for the PRISMA checklist, refer to Supplementary Table S1. The study protocol has been registered with PROSPERO (CRD42022313299). We carried out a systematic search through MEDLINE (via PubMed), Web of Science, Scopus, Cochrane library, and Google Scholar from the inception of the COVID-19 report (December 2019) to August 15, 2022. Our search also included review publications, editorials, letters to editors, conference papers, as well as the references of all the studies included. The Keywords used were "SARS-CoV-2 vaccine", "COVID-19 vaccine", "facial nerve palsy," and "Bell's palsy" (Supplementary Table S2). No restriction on the study design, age of the participants, literature language, or any other restriction was imposed. The study was exempt from ethical approval by the local institutional ethics committee, as we utilized the previously published data.

Eligibility criteria

The study participants were individuals who had undergone SARS-CoV-2 vaccination with all widely administered SARS-CoV-2 vaccine platforms, including mRNA, viral vector, inactivated, protein subunit, etc. The participants were compared with individuals either receiving saline placebo or other vaccines (in case of RCTs) or unvaccinated (in case of observational studies). The outcome of interest was BP occurring as an adverse event in the time frame after the vaccination or the respective time frame in the placebo recipients or unvaccinated matched participants. The BP diagnosis was determined based on the neurologist-confirmed clinical criteria and/or the ICD-10 codes, as mentioned by each study. We excluded any study reporting facial paralysis due to known etiologies, including stroke, GBS, thromboembolic

events, Lyme disease, bacterial otitis media, Ramsey Hunt syndrome (RHS), sarcoidosis, and multiple sclerosis (MS).

Selection process

For data selection, the records obtained from different search databases were first transferred to Endnote software. After removing duplicate records, two independent researchers (MeJ and YP) screened all articles from the systematic search through a stepwise process. Firstly, all records were screened using the title and abstracts. Potentially eligible records were further evaluated using the full texts in the second step. Ultimately, the records which did not meet the pre-established eligibility criteria were excluded. Conflicts were resolved by joint discussions and the consensus of the authors.

Data extraction

The data of interest were extracted as follows: (a) study-related variables (first author's name, publication year, sample size, study design, and the presence of control group and its general description), (b) vaccine-related variables including vaccine type, number of doses received, (c) demographic and baseline variables including age, sex, past medical history, prior SARS-CoV-2 infection, prior herpes zoster infection, history of BP, and drug history, (d) clinical and BP-related variables including number of patients presenting BP, BP laterality, concomitant signs and symptoms, initial physical examination, duration from vaccination to the event, paraclinical assessments, treatments, outcome, and recurrence if followed up. Two independent researchers (SI and MaJ) extracted the data and filled out the pre-designed forms. The discrepancy was dealt with through the consensus of two of the authors (AR and MeJ).

Quality assessment

We assessed the quality of included studies and evaluated the risk of bias using the Newcastle-Ottawa scale (NOS) for cross-sectional studies, self-controlled case series (SCCS), case controls, and cohorts (studies with an overall score of ≥7 points were considered high quality) (32, 33), and the Cochrane assessment tool for Randomized Controlled Trials (RCT) (classifying studies as unclear, low- or high-risk) (34). Two independent researchers (DS and MA) performed the risk of bias assessment, and conflicts were resolved via consensus.

Data synthesis

The included studies for quantitative synthesis were pooled within four sections. In the first section, four studies corresponding to the phase-3 RCTs of the major SARS-CoV-2 vaccines, i.e., Pfizer/BioNTech, Moderna, Janssen, and Oxford/AstraZeneca, were evaluated. The BP occurrence was compared between vaccine and saline placebo recipients within subgroups of viral vector and mRNA vaccines. In the second section, all observational studies comparing BP in mRNA vaccine recipients and the unvaccinated matched individuals were investigated. The third section compared the odds of BP in Pfizer/BioNTech vs. Oxford/AstraZeneca

recipients. The fourth section pooled the risk ratio (RR) of Bell's palsy in SARS-CoV-2 infected patients vs. SARS-CoV-2 vaccine recipients.

Statistical analysis

All statistical analyses were performed using R version 4.2.1, implementing the R package 'meta' version 5.2-0 (35), using the Mantel-Haenszel method (36, 37). For the sections one and two of data analysis, the 'metabin' function was utilized to pool the dichotomous data on the incidence of BP, and the odds ratio (OR), with the corresponding 95% confidence intervals (CIs), was opted as the measure of effect. Subsequently, for the sections three and four, the 'metagen' function was used to pool the measures of effect (OR and RR with the corresponding 95% CIs).

The between-study heterogeneity was assessed by the Cochran's Q statistic, $\tau 2$ using the restricted maximum-likelihood (REML) estimator, and I^2 index (38, 39). Based on the I^2 index, it was decided whether to choose between the fixed-effects or random-effects models. If $I^2 \geq 50\%$, representing substantial heterogeneity, the random-effects model was used; otherwise, the fixed-effects model was used. Publication bias was assessed visually with funnel plots, and asymmetry was statistically tested using the Egger's test as well as the Peter's test (a method of choice for binary outcomes) (40, 41). A two-tailed p-value < 0.05 was considered significant.

Results

Study selection

A summary of the inclusion process is represented in a PRISMA flow diagram in Figure 1. An overall 643 records were identified through our systematic search method. Of these, 180 were removed as being duplicate records. Thereafter, 463 records were screened by title and abstract, and 84 remained for further evaluation. All 84 records were retrieved, and full texts were assessed in terms of eligibility for our study. Among them, 17 records overlapped other studies, 9 records were commentaries and corrections on other articles, and 8 did not meet the inclusion criteria. Thus, 34 records were excluded, and the remaining 50 records entered our study. Of the 50 studies, 17 articles comparing BP incidence in SARS-CoV-2 vaccinated, and control groups that could be pooled were included in the meta-analysis, and the remaining 33 were only included in the qualitative synthesis, i.e., the characteristics of which were extracted and formatted into a table (supplementary Table S8).

Of the excluded studies, three records (42-44) were the reports of preliminary results of the major SARS-CoV-2 vaccine phase-3 clinical trials, of which the records reporting the final analyses were included instead. In the case of overlapping studies, the study with the highest score in terms of quality assessment was deemed appropriate and was included in the study. Three studies (45-47) met the inclusion criteria; however, they used the same patient databases, hence, overlapping considerably with the included studies from Hong Kong. Lastly,

four overlapping studies reported the data retrieved from the Vaccine Adverse Event Reporting System (VAERS) database, of which one (48) was included with the highest quality score, and the remainder were excluded (29, 49, 50). Similarly, three overlapping studies used the data obtained from the WHO VigiBase database, two of which were excluded (51, 52).

Study characteristics

The 50 included studies comprised 22 case reports and case series (30, 53-73), two self-controlled case series (SCCS) (74, 75), two case controls (76, 77), three cross sectionals (78-80), 16 cohorts (48, 81-95), and five RCTs (96-100). A summary of the characteristics of the included studies is represented in Table 1 (case reports and case series are summarized in the supplementary Table S9) and detailed in the supplementary Table S8.

Quality appraisal

Of the 5 RCTs, three had a low risk of bias (96-98), and two were unclear (99, 100) in the criterion "D5: detection bias" of the Cochrane assessment tool but were low risk in the rest of the criteria. The mean NOS for cohorts, case controls, cross-sectionals, and SCCSs were 6.87, 7.5, 4, and 8.5, respectively. All records included in the meta-analysis had NOS of \geq 7. The results are demonstrated in the supplementary Figure S1 and Tables S4, S5, S6, and S7.

RCTs: vaccinated vs. saline placebo

Four RCTs that reported BP as an adverse event were included in the first meta-analysis (96-99). These consisted of the final results of the phase-3 trials of the four major SARS-CoV-2 vaccines approved and widely administered worldwide- Pfizer/BioNTech, Moderna, Janssen, and Oxford/AstraZeneca. Of note, the study by Voysey et al. was not included in the meta-analysis since they reported four RCTs of Oxford/AstraZeneca in three distinct geographical regions, in which the placebo was not solely specified as saline, but viral vaccines other than SARS-CoV-2 vaccines, i.e., meningococcal group A, C, W, and Y conjugate vaccine (MenACWY) (100).

The meta-analysis was composed of two subgroups of mRNA vaccines (Pfizer/BioNTech and Moderna) and viral-vector vaccines (Janssen and Oxford/AstraZeneca) (Figure 2). For the mRNA vaccine subgroup, there were significantly increased odds of BP in the vaccinated group compared to the placebo (OR: 3.57 (95% CI 1.09-11.67), I²=0%; Cochran p-value Q=0.46). However, for the viral-vector vaccine subgroup, the analysis yielded insignificant results (OR: 1.80 (95% CI 0.26-12.35), I²=0%; Cochran p-value Q=0.89). Overall, taken together all four trials, BP occurred significantly higher in the vaccine group (77,525 doses) versus placebo (66,682 individuals) (OR: 3.00 (95% CI 1.10-8.18), I²=0%; Cochran p-value Q=0.84). Addressing the publication bias, the funnel plots are provided in the supplementary Figure S1. The Egger's and Peter's tests both yielded nonsignificant results (p-value=0.85 and p-value=0.73, respectively); hence no publication bias was detected.

Observational studies on mRNA vaccines: vaccinated vs. unvaccinated

There were nine studies dealing with the adverse events reported subsequent to the administration of the first and/or second dose of SARS-CoV-2 mRNA vaccines, i.e., Moderna and Pfizer/BioNTech, ranging from the age of 12 and above. Overall, 13,518,026 vaccine doses as the vaccinated group were compared to 13,510,701 matched unvaccinated individuals (Figure 3). The analysis was divided into two subgroups of cohorts and case controls. In the cohorts (81, 85-87, 89, 94), the analysis indicated no significant evidence of increased odds of BP in the vaccinated group compared to the unvaccinated group (OR: 0.59 (95% CI 0.34-1.01), I²=94%; p-value of Cochran Q <0.01). Likewise, in the case controls (76, 77), not such a significant result was yielded (OR: 1.37 (95% CI 0.64-2.90), I²=54%; Cochran Q p-value=0.14). The overall meta-analysis as well yielded insignificant results (OR: 0.70 (95% CI 0.42-1.16), I²=94%; Cochran Q p-value<0.01). After all, no publication bias was observed among the studies with the Peter's test p-value of 0.34 (funnel plot in the supplementary Figure S2).

Pfizer/BioNTech vs. Oxford/AstraZeneca

Between 22,760,698 first-dose Pfizer/BioNTech recipients and 22,978,880 first-dose Oxford/AstraZeneca recipients, events of BP in a 21-day interval after the vaccination was compared (74, 91, 92) (Figure 4). For the analysis from the study by Li et al., only the data obtained from the Spanish database of Information System for Research in Primary Care (SIDIAP) were utilized for data pooling, and the data from the UK was excluded due to database overlapping with the study by Patone et al. (91, 92). The odds of developing BP after Pfizer/BioNTech compared with the Oxford/AstraZeneca were deemed insignificant (OR: 0.97 (95% CI 0.82-1.15), I²=0%; Cochran Q p-value=0.67). The funnel plots for the publication bias are represented in the supplementary Figure S3, and the Egger's test yielded a p-value of 0.64; hence no publication bias was present.

SARS-CoV-2 infections vs. SARS-CoV-2 vaccine

We compared a total of 2,641,398 SARS-CoV-2 infected individuals with 36,988,718 SARS-CoV-2 vaccine recipients regarding the BP occurrence (79, 91, 92) (Figure 5). The risk of developing BP subsequent to the SARS-CoV-2 infection significantly surpassed that of the SARS-CoV-2 vaccine (RR: 4.03 (95% CI 1.78-9.12), I^2 =96%; p-value of Cochran Q <0.01). Of the pooled studies, only Tamaki et al. reported a pre-calculated RR (79). The funnel plot is demonstrated in the supplementary Figure S4. The Egger's test yielded a p-value of 0.79, thus showing no publication bias.

Discussion

To the best of our knowledge, this is the first systematic review and meta-analysis addressing the BP incidence subsequent to the SARS-CoV-2 vaccination. This study has pooled data on over 53 million vaccine doses for meta-analysis. In this context, we have compared two major SARS-CoV-2 vaccine platforms in terms of BP occurrence in over 50 million doses. The BP

occurrence following the SARS-CoV-2 infection was also compared with the SARS-CoV-2 vaccine in around 40 million individuals.

Our analysis of the RCTs shows that among all SARS-CoV-2 vaccine recipients, the odds of BP occurrence were significantly increased in the mRNA vaccine subgroup compared to the saline placebo recipients. In the viral-vector vaccine subgroup, however, no such significant difference was observed. The analysis of observational studies shows that the odds of BP incidence after SARS-CoV-2 mRNA vaccines did not significantly differ from those who did not receive any vaccine. Furthermore, comparing the first dose recipients of Pfizer/BioNTech and Oxford/AstraZeneca vaccines, the risk of developing BP within 21 days of the vaccination was not significantly different. Finally, based on our analysis, the SARS-CoV-2 infection contributes to a significant four-fold increase in BP risk compared to SARS-CoV-2 vaccines.

Several mechanisms have been considered to explicate the underlying pathophysiology of BP. One proposed mechanism is the nerve compression within the temporal bone due to the perineural inflammation and subsequent edematous nerve bundles in response to reactivation of a dormant virus (101), such as in the case of Ramsey Hunt syndrome with the herpes virus (53). Likewise, it is speculated that the vaccine antigens that can reactivate Tcells by mimicking human cell surface molecules may elicit an autoimmune response (77). BP, as an adverse event of vaccination, is not a newly encountered phenomenon only with SARS-CoV-2 vaccines. In an attempt to look for evidence of vaccines triggering BP, Ozonoff et al. conducted a brief review indicating the association of BP with intranasal influenza vaccine, seasonal influenza vaccine, H1N1 influenza vaccines, and meningococcal conjugate vaccine (102). The intranasal inactivated influenza vaccine was suggested to be strongly linked with BP through mediating inflammation due to containing Escherichia coli heat-labile enterotoxin. However, such an association is confirmed solely in animal studies (103, 104). Likewise, the seasonal parenteral inactivated influenza vaccine was shown in the surveys of the VAERS database to have a potential association with BP incidence, as manifested by surveys of the VAERS database (105, 106). Monovalent H1N1 influenza vaccines with immunologic adjuvants were as well significantly associated with BP (107, 108). Similarly, the quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) was also indicated to be significantly linked to increased incidence of BP (109). SARS-CoV-2 vaccines, however, do not contain adjuvants that mediate the immune response. Instead, the virus mRNA in the vaccines might interact with the immune cellular membranes and elicit an innate immune response (102), which in turn may trigger BP similar to the cases reported with interferon treatment (110, 111).

The present study has several limitations. Most importantly, we have used the published data, and no individual-patient-level data was available in this study. This hampered our ability to perform subgroup analyses based on parameters such as age, sex, vaccine dose, or vaccination to event timespan. Also, it was not possible to control for some of the known BP

risk factors, such as diabetes, obesity, hypertension, upper respiratory disease, or pregnancy, as the majority of the studies have not provided sufficient data on these risk factors (101). In addition, it should be considered that the recorded BP cases following vaccination might have been prone to a reporting bias due to the heightened awareness as the researchers have constantly sought to record adverse events amidst the new pandemic. Furthermore, not all the studies have split the results of the first and second vaccine doses. Instead, they have reported the combined data, and their analyses were based on the events per vaccine dose and not based on the events per participant. Notably, none of the studies had any data from children younger than 12 years old, and this inclusion bias impedes the generalizability of the findings to this younger age range. Finally, studies comparing the BP incidence after SARS-CoV-2 infection with SARS-CoV-2 vaccines included different time periods and did not mention the prevalent SARS-CoV-2 subtypes at the time each study was conducted. When attempting to compare with other vaccines and diseases, SARS-CoV-2 vaccine studies did not provide sufficient data for pooling. All in all, these limitations may have impacted heterogeneity among studies, leading to potential confounders for analysis.

Conclusion

SARS-CoV-2 vaccines (mRNA and viral vector) in the analysis of RCTs demonstrated significantly increased odds of developing BP versus placebo. The analysis of the observational studies showed that mRNA SARS-CoV-2 vaccinated participants had no significant rise in BP incidence versus the unvaccinated participants. The incidence of BP in those who received Pfizer/BioNTech or Oxford/Astrazeneca vaccines did not differ significantly. Notably, SARS-CoV-2 infection compared to the SARS-CoV-2 vaccine was linked with a four-fold augmented BP risk incidence. As we report these associations between SARS-CoV-2 vaccines and BP, we hereby reiterate that these associations do not equate to causality; hence further research is required to establish the documented associations.

Supplementary information

The supplementary materials are available at (link)

Author contribution

Ali Rafati: conceptualization, formal analysis, investigation, data curation, methodology, visualization, wrote the original draft, reviewed, and edited the manuscript.

Yeganeh Pasebani: conceptualization, formal analysis investigation data curation, methodology, visualization, wrote the original draft, reviewed, and edited the manuscript.

Melika Jameie: investigation, data curation, methodology, visualization, wrote the original draft, reviewed, and edited the manuscript.

Yuchen Yang: investigation, data curation, methodology, formal analysis, reviewed and edited the manuscript.

Mana Jameie: investigation, data curation, reviewed and edited the manuscript.

Saba Ilkhani: investigation, data curation, reviewed and edited the manuscript.

Mobina Amanollahi: investigation, data curation, reviewed and edited the manuscript.

Delaram Sakhaei: investigation, data curation, reviewed and edited the manuscript. **Mehran Rahimlou:** project administration, supervised, reviewed, and edited the manuscript. Amir Kheradmand: project administration, supervised, validated, reviewed, and edited the

manuscript.

All authors read and approved the final manuscript.

Conflicts of interest

Hereby, we declare no conflict of interest.

Funding sources

None.

Data availability

This study does not contain any original data to share. All analyses were performed upon previously published articles.

Acknowledgments

None.

References

- 1. Tiemstra JD, Khatkhate N. Bell's palsy: diagnosis and management. American family physician. 2007;76(7):997-1002.
- 2. Warner MJ, Hutchison J, Varacallo M. Bell Palsy. StatPearls. Treasure Island (FL): StatPearls Publishing
- Copyright © 2022, StatPearls Publishing LLC.; 2022.
- 3. Zhang W, Xu L, Luo T, Wu F, Zhao B, Li X. The etiology of Bell's palsy: a review. J Neurol. 2020;267(7):1896-905.
- 4. Goh Y, Beh DLL, Makmur A, Somani J, Chan ACY. Pearls & Dy-sters: Facial nerve palsy in COVID-19 infection. Neurology. 2020;95(8):364.
- 5. WHO Coronavirus (COVID-19) Dashboard: WHO Coronavirus (COVID-19) Dashboard; 2022 [cited 2022. Available from: https://covid19.who.int/.
- 6. Misra S, Kolappa K, Prasad M, Radhakrishnan D, Thakur KT, Solomon T, et al. Frequency of Neurologic Manifestations in COVID-19: A Systematic Review and Meta-analysis. Neurology. 2021;97(23):e2269-e81.
- 7. Danza P, Koo TH, Haddix M, Fisher R, Traub E, K OY, et al. SARS-CoV-2 Infection and Hospitalization Among Adults Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance Los Angeles County, California, November 7, 2021-January 8, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(5):177-81.
- 8. Taylor CA, Whitaker M, Anglin O, Milucky J, Patel K, Pham H, et al. COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Delta and Omicron Variant Predominance, by Race/Ethnicity and Vaccination Status COVID-NET, 14 States, July 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(12):466-73.
- 9. Vilches TN, Sah P, Moghadas SM, Shoukat A, Fitzpatrick MC, Hotez PJ, et al. COVID-19 hospitalizations and deaths averted under an accelerated vaccination program in northeastern and southern regions of the USA. Lancet Reg Health Am. 2022;6:100147.
- 10. Fan Y-J, Chan K-H, Hung IF-N. Safety and Efficacy of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Different Vaccines at Phase 3. Vaccines. 2021;9(9):989.
- 11. Anand P, Stahel VP. Review the safety of Covid-19 mRNA vaccines: a review. Patient Saf Surg. 2021;15(1):20.
- 12. Vaccines for COVID-19 Centers for Disease Control and Prevention [cited 2022 July 2]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html.
- 13. Safety of COVID-19 Vaccines: World Health Organization; 2021 [updated 31 March 2021; cited 2022 July 2]. Available from: https://www.who.int/news-room/feature-stories/detail/safety-of-covid-19-vaccines.
- 14. Jacobson MA, Zakaria A, Maung Z, Hart C, McCalmont TH, Fassett M, et al. Incidence and Characteristics of Delayed Injection Site Reaction to the mRNA-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine (Moderna) in a Cohort of Hospital Employees. Clin Infect Dis. 2022;74(4):591-6.
- 15. Sohrabi M, SobheRakhshankhah E, Ziaei H, AtaeeKachuee M, Zamani F. Acute liver failure after vaccination against of COVID-19; a case report and review literature. Respir Med Case Rep. 2022;35:101568.
- 16. Lim JH, Kim MS, Kim YJ, Han MH, Jung HY, Choi JY, et al. New-Onset Kidney Diseases after COVID-19 Vaccination: A Case Series. Vaccines (Basel). 2022;10(2).
- 17. Liu R, Pan J, Zhang C, Sun X. Cardiovascular Complications of COVID-19 Vaccines. Front Cardiovasc Med. 2022;9:840929.
- 18. Assiri SA, Althaqafi RMM, Alswat K, Alghamdi AA, Alomairi NE, Nemenqani DM, et al. Post COVID-19 Vaccination-Associated Neurological Complications. Neuropsychiatr Dis Treat. 2022;18:137-54.

- 19. Castaldo M, Waliszewska-Prosół M, Koutsokera M, Robotti M, Straburzyński M, Apostolakopoulou L, et al. Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis. J Headache Pain. 2022;23(1):41.
- 20. Sekiguchi K, Watanabe N, Miyazaki N, Ishizuchi K, Iba C, Tagashira Y, et al. Incidence of headache after COVID-19 vaccination in patients with history of headache: A cross-sectional study. Cephalalgia. 2022;42(3):266-72.
- 21. Hanson KE, Goddard K, Lewis N, Fireman B, Myers TR, Bakshi N, et al. Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink. JAMA Network Open. 2022;5(4):e228879-e.
- 22. Yagi Y, Asami Y, Kyoya M, Yokota T. Cerebral venous sinus thrombosis after mRNA-based COVID-19 vaccination. Neurol Sci. 2022;43(1):41-3.
- 23. Palaiodimou L, Stefanou MI, Katsanos AH, Aguiar de Sousa D, Coutinho JM, Lagiou P, et al. Cerebral Venous Sinus Thrombosis and Thrombotic Events After Vector-Based COVID-19 Vaccines: A Systematic Review and Meta-analysis. Neurology. 2021;97(21):e2136-e47.
- 24. Eom H, Kim SW, Kim M, Kim YE, Kim JH, Shin HY, et al. Case Reports of Acute Transverse Myelitis Associated With mRNA Vaccine for COVID-19. J Korean Med Sci. 2022;37(7):e52.
- 25. Finsterer J. Neurological side effects of SARS-CoV-2 vaccinations. Acta Neurol Scand. 2022;145(1):5-9.
- 26. Somasundara D, Sullivan F. Management of Bell's palsy. Aust Prescr. 2017;40(3):94-7.
- 27. Kafle DR, Thakur SK. Evaluation of prognostic factors in patients with Bell's palsy. Brain Behav. 2021;11(11):e2385.
- 28. Cirillo N, Doan R. The association between COVID-19 vaccination and Bell's palsy. Lancet Infect Dis. 2022;22(1):5-6.
- 29. Sato K, Mano T, Niimi Y, Toda T, Iwata A, Iwatsubo T. Facial nerve palsy following the administration of COVID-19 mRNA vaccines: analysis of a self-reporting database. Int J Infect Dis. 2021;111:310-2.
- 30. Yu BY, Cen LS, Chen T, Yang TH. Bell's palsy after inactivated COVID-19 vaccination in a patient with history of recurrent Bell's palsy: A case report. World J Clin Cases. 2021;9(27):8274-9.
- 31. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj. 2021;372:n71.
- 32. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603-5.
- 33. Wachira VK, Peixoto HM, de Oliveira MRF. Proposal of a Quality Assessment tool for the Evaluation of the Methodological Quality of Self-Controlled Case Series and Self-Controlled Risk Interval Study Designs. 2022.
- 34. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Bmj. 2011;343:d5928.
- 35. Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153-60.
- 36. Greenland S, Robins JM. Estimation of a common effect parameter from sparse follow-up data. Biometrics. 1985;41(1):55-68.
- 37. Robins J, Breslow N, Greenland S. Estimators of the Mantel-Haenszel variance consistent in both sparse data and large-strata limiting models. Biometrics. 1986;42(2):311-23.
- 38. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-58.
- 39. Viechtbauer W. Bias and Efficiency of Meta-Analytic Variance Estimators in the Random-Effects Model. Journal of Educational and Behavioral Statistics. 2005;30(3):261-93.
- 40. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. Jama. 2006;295(6):676-80.
- 41. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Bmj. 1997;315(7109):629-34.

- 42. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403-16.
- 43. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-15.
- 44. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021;384(23):2187-201.
- 45. Wan EYF, Chui CSL, Ng VWS, Wang Y, Yan VKC, Lam ICH, et al. mRNA (BNT162b2) COVID-19 vaccination increased risk of Bell's palsy: a nested case control and self-controlled case series study. Clin Infect Dis. 2022.
- 46. Wong CKH, Lau KTK, Xiong X, Au ICH, Lai FTT, Wan EYF, et al. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study. PLoS Med. 2022;19(6):e1004018.
- 47. Xiong X, Wong CKH, Au ICH, Lai FTT, Li X, Wan EYF, et al. Safety of Inactivated and mRNA COVID-19 Vaccination Among Patients Treated for Hypothyroidism: A Population-Based Cohort Study. Thyroid. 2022;32(5):505-14.
- 48. Frontera JA, Tamborska AA, Doheim MF, Garcia-Azorin D, Gezegen H, Guekht A, et al. Neurological Events Reported after COVID-19 Vaccines: An Analysis of Vaccine Adverse Event Reporting System. Ann Neurol. 2022;91(6):756-71.
- 49. Sadeghalvad M, Mansourabadi AH, Noori M, Nejadghaderi SA, Masoomikarimi M, Alimohammadi M, et al. Recent developments in SARS-CoV-2 vaccines: A systematic review of the current studies. Rev Med Virol. 2022:e2359.
- 50. Singh A, Khillan R, Mishra Y, Khurana S. The safety profile of COVID-19 vaccinations in the United States. American Journal of Infection Control. 2022;50(1):15-9.
- 51. Dutta S, Kaur R, Charan J, Bhardwaj P, Ambwani SR, Babu S, et al. Analysis of Neurological Adverse Events Reported in VigiBase From COVID-19 Vaccines. Cureus. 2022;14(1):e21376.
- 52. Renoud L, Khouri C, Revol B, Lepelley M, Perez J, Roustit M, et al. Association of Facial Paralysis With mRNA COVID-19 Vaccines: A Disproportionality Analysis Using the World Health Organization Pharmacovigilance Database. JAMA Intern Med. 2021;181(9):1243-5.
- 53. Burrows A, Bartholomew T, Rudd J, Walker D. Sequential contralateral facial nerve palsies following COVID-19 vaccination first and second doses. BMJ Case Rep. 2021;14(7).
- 54. Cellina M, D'Arrigo A, Floridi C, Oliva G, Carrafiello G. Left Bell's palsy following the first dose of mRNA-1273 SARS-CoV-2 vaccine: A case report. Clin Imaging. 2022;82:1-4.
- 55. Colella G, Orlandi M, Cirillo N. Bell's palsy following COVID-19 vaccination. J Neurol. 2021;268(10):3589-91.
- 56. Gómez de Terreros Caro G, Gil Díaz S, Pérez Alé M, Martínez Gimeno ML. Bell's palsy following COVID-19 vaccination: a case report. Neurologia (Engl Ed). 2021;36(7):567-8.
- 57. Martin-Villares C, Vazquez-Feito A, Gonzalez-Gimeno MJ, de la Nogal-Fernandez B. Bell's palsy following a single dose of mRNA SARS-CoV-2 vaccine: a case report. J Neurol. 2022;269(1):47-8.
- 58. Mason MC, Liaqat A, Morrow J, Basso R, Gujrati Y. Bilateral Facial Nerve Palsy and COVID-19 Vaccination: Causation or Coincidence? Cureus. 2021;13(8):e17602.
- 59. Obermann M, Krasniqi M, Ewers N, Fayad J, Haeberle U. Bell's palsy following COVID-19 vaccination with high CSF antibody response. Neurol Sci. 2021;42(11):4397-9.
- 60. Pothiawala S. Bell's palsy after second dose of moderna covid-19 vaccine: Coincidence or causation? Acta Medica Lituanica. 2021;28(2):262-5.
- 61. Repajic M, Lai XL, Xu P, Liu A. Bell's Palsy after second dose of Pfizer COVID-19 vaccination in a patient with history of recurrent Bell's palsy. Brain Behav Immun Health. 2021;13:100217.
- 62. Tahir N, Koorapati G, Prasad S, Jeelani HM, Sherchan R, Shrestha J, et al. SARS-CoV-2 Vaccination-Induced Transverse Myelitis. Cureus. 2021;13(7):e16624.
- 63. Corrêa DG, Cañete LAQ, Dos Santos GAC, de Oliveira RV, Brandão CO, da Cruz LCH, Jr. Neurological symptoms and neuroimaging alterations related with COVID-19 vaccine: Cause or coincidence? Clin Imaging. 2021;80:348-52.

- 64. Iftikhar H, Noor SMU, Masood M, Bashir K. Bell's Palsy After 24 Hours of mRNA-1273 SARS-CoV-2 Vaccine. Cureus. 2021;13(6):e15935.
- 65. Ish S, Ish P. Facial nerve palsy after COVID-19 vaccination A rare association or a coincidence. Indian Journal of Ophthalmology. 2021;69(9):2550-U644.
- 66. Mussatto CC, Sokol J, Alapati N. Bell's palsy following COVID-19 vaccine administration in HIV+ patient. Am J Ophthalmol Case Rep. 2022;25:101259.
- 67. Nishizawa Y, Hoshina Y, Baker V. Bell's palsy following the Ad26.COV2.S COVID-19 vaccination. Qjm. 2021;114(9):657-8.
- 68. Kaulen LD, Doubrovinskaia S, Mooshage C, Jordan B, Purrucker J, Haubner C, et al. Neurological autoimmune diseases following vaccinations against SARS-CoV-2: a case series. European Journal of Neurology. 2022;29(2):555-63.
- 69. González-Enríquez JO. [Bell's Palsy Secondary to COVID-19 Vaccine Pfizer: Case report]. Rev Med Inst Mex Seguro Soc. 2022;60(2):224-8.
- 70. Kharoubi S. [Peripheral facial palsy following COVID-19 vaccination: a case report]. Pan Afr Med J. 2021;40:244.
- 71. Mirmosayyeb O, Barzegar M, Rezaei M, Baharlouie N, Shaygannejad V. Bell's palsy after Sputnik V COVID-19 (Gam-COVID-Vac) vaccination. Clin Case Rep. 2022;10(2):e05468.
- 72. Poudel S, Nepali P, Baniya S, Shah S, Bogati S, Nepal G, et al. Bell's palsy as a possible complication of mRNA-1273 (Moderna) vaccine against COVID-19. Ann Med Surg (Lond). 2022;78:103897.
- 73. Hamid R, Korkmazer B, Kochan Kizilkilic E, Arman GM, Ozogul M, Kargın OA, et al. Potential Association Between COVID-19 Vaccination and Facial Palsy: Three Cases With Neuroimaging Findings. Ear Nose Throat J. 2022:1455613221113818.
- 74. Ab Rahman N, Lim MT, Lee FY, Lee SC, Ramli A, Saharudin SN, et al. Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: A self-controlled case series study. Vaccine. 2022;40(32):4394-402.
- 75. Walker JL, Schultze A, Tazare J, Tamborska A, Singh B, Donegan K, et al. Safety of COVID-19 vaccination and acute neurological events: A self-controlled case series in England using the OpenSAFELY platform. Vaccine. 2022;40(32):4479-87.
- 76. Shemer A, Pras E, Einan-Lifshitz A, Dubinsky-Pertzov B, Hecht I. Association of COVID-19 Vaccination and Facial Nerve Palsy: A Case-Control Study. JAMA Otolaryngol Head Neck Surg. 2021;147(8):739-43.
- 77. Wan EYF, Chui CSL, Lai FTT, Chan EWY, Li X, Yan VKC, et al. Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study. Lancet Infectious Diseases. 2022;22(1):64-72.
- 78. El-Shitany NA, Harakeh S, Badr-Eldin SM, Bagher AM, Eid B, Almukadi H, et al. Minor to Moderate Side Effects of Pfizer-BioNTech COVID-19 Vaccine Among Saudi Residents: A Retrospective Cross-Sectional Study. Int J Gen Med. 2021;14:1389-401.
- 79. Tamaki A, Cabrera CI, Li S, Rabbani C, Thuener JE, Rezaee RP, et al. Incidence of Bell Palsy in Patients With COVID-19. JAMA Otolaryngol Head Neck Surg. 2021;147(8):767-8.
- 80. Hüls A, Feany PT, Zisman SI, Costa ACS, Dierssen M, Balogh R, et al. COVID-19 Vaccination of Individuals with Down Syndrome—Data from the Trisomy 21 Research Society Survey on Safety, Efficacy, and Factors Associated with the Decision to Be Vaccinated. Vaccines. 2022;10(4).
- 81. Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. New England Journal of Medicine. 2021;385(12):1078-90.
- 82. Davidov Y, Tsaraf K, Cohen-Ezra O, Likhter M, Ben Yakov G, Levy I, et al. Immunogenicity and Adverse Effects of the 2-Dose BNT162b2 Messenger RNA Vaccine Among Liver Transplantation Recipients. Liver Transplantation. 2022;28(2):215-23.

- 83. Filippatos F, Tatsi EB, Dellis C, Dessypris N, Syriopoulou V, Michos A. Association of clinical and epidemiological characteristics with COVID-19 BNT162b2 mRNA vaccine short-term adverse reactions in healthcare workers. Human Vaccines & Immunotherapeutics.
- 84. Tan JTC, Tan C, Teoh J, Wahab MT, Tan GZ, Chin RYZ, et al. Adverse reactions and safety profile of the mRNA COVID-19 vaccines among Asian military personnel. Ann Acad Med Singap. 2021;50(11):827-37.
- 85. Klein NP, Lewis N, Goddard K, Fireman B, Zerbo O, Hanson KE, et al. Surveillance for Adverse Events After COVID-19 mRNA Vaccination. Jama. 2021;326(14):1390-9.
- 86. Shasha D, Bareket R, Sikron FH, Gertel O, Tsamir J, Dvir D, et al. Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine: historical cohort study. Clin Microbiol Infect. 2022;28(1):130-4.
- 87. McMurry R, Lenehan P, Awasthi S, Silvert E, Puranik A, Pawlowski C, et al. Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines. Med (N Y). 2021;2(8):965-78.e5.
- 88. Shibli R, Barnett O, Abu-Full Z, Gronich N, Najjar-Debbiny R, Doweck I, et al. Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study: BNT162b2 mRNA COVID-19 vaccine and Bell's palsy. The Lancet Regional Health Europe. 2021;11.
- 89. Bardenheier BH, Gravenstein S, Blackman C, Gutman R, Sarkar IN, Feifer RA, et al. Adverse events following mRNA SARS-CoV-2 vaccination among U.S. nursing home residents. Vaccine. 2021;39(29):3844-51.
- 90. Koh JS, Hoe RHM, Yong MH, Chiew HJ, Goh YH, Yong KP, et al. Hospital-based observational study of neurological disorders in patients recently vaccinated with COVID-19 mRNA vaccines. Journal of the Neurological Sciences. 2021;430.
- 91. Patone M, Handunnetthi L, Saatci D, Pan J, Katikireddi SV, Razvi S, et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat Med. 2021;27(12):2144-53.
- 92. Li X, Raventós B, Roel E, Pistillo A, Martinez-Hernandez E, Delmestri A, et al. Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis. Bmj. 2022;376:e068373.
- 93. Lai FTT, Huang L, Chui CSL, Wan EYF, Li X, Wong CKH, et al. Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong. Nat Commun. 2022;13(1):411.
- 94. Lai FTT, Chua GT, Chan EWW, Huang L, Kwan MYW, Ma T, et al. Adverse events of special interest following the use of BNT162b2 in adolescents: a population-based retrospective cohort study. Emerg Microbes Infect. 2022;11(1):885-93.
- 95. Noseda R, Ripellino P, Ghidossi S, Bertoli R, Ceschi A. Reporting of Acute Inflammatory Neuropathies with COVID-19 Vaccines: Subgroup Disproportionality Analyses in VigiBase. Vaccines (Basel). 2021;9(9).
- 96. El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, et al. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med. 2021;385(19):1774-85.
- 97. Thomas SJ, Moreira ED, Jr., Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med. 2021;385(19):1761-73.
- 98. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S. N Engl J Med. 2022;386(9):847-60.
- 99. Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, et al. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N Engl J Med. 2021;385(25):2348-60.
- 100. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111.

- 101. Baugh RF, Basura GJ, Ishii LE, Schwartz SR, Drumheller CM, Burkholder R, et al. Clinical practice guideline: Bell's palsy. Otolaryngol Head Neck Surg. 2013;149(3 Suppl):S1-27.
- 102. Ozonoff A, Nanishi E, Levy O. Bell's palsy and SARS-CoV-2 vaccines. Lancet Infect Dis. 2021;21(4):450-2.
- 103. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med. 2004;350(9):896-903.
- 104. Couch RB. Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy. N Engl J Med. 2004;350(9):860-1.
- 105. Zhou W, Pool V, DeStefano F, Iskander JK, Haber P, Chen RT. A potential signal of Bell's palsy after parenteral inactivated influenza vaccines: reports to the Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001. Pharmacoepidemiol Drug Saf. 2004;13(8):505-10.
- 106. Kamath A, Maity N, Nayak MA. Facial Paralysis Following Influenza Vaccination: A Disproportionality Analysis Using the Vaccine Adverse Event Reporting System Database. Clin Drug Investig. 2020;40(9):883-9.
- 107. Huang WT, Huang WI, Huang YW, Hsu CW, Chuang JH. The reporting completeness of a passive safety surveillance system for pandemic (H1N1) 2009 vaccines: a capture-recapture analysis. Vaccine. 2012;30(12):2168-72.
- 108. Bardage C, Persson I, Ortqvist A, Bergman U, Ludvigsson JF, Granath F. Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden. Bmj. 2011;343:d5956.
- 109. Tseng HF, Sy LS, Ackerson BK, Hechter RC, Tartof SY, Haag M, et al. Safety of Quadrivalent Meningococcal Conjugate Vaccine in 11- to 21-Year-Olds. Pediatrics. 2017;139(1).
- 110. Yalçındağ FN, Alay C. Bell's palsy during interferon alpha 2a treatment in a case with Behçet uveitis. F1000Res. 2013;2:245.
- 111. Hwang I, Calvit TB, Cash BD, Holtzmuller KC. Bell's palsy: a rare complication of interferon therapy for hepatitis C. Dig Dis Sci. 2004;49(4):619-20.

Figure 1- PRISMA flow diagram of the systematic search




Figure 2- Forest plot representing Bell's palsy events in groups of vaccine recipients vs. saline placebo recipients (data from RCTs).




Figure 3- Forest plot representing Bell's palsy events in groups of mRNA-vaccinated participants vs. unvaccinated participants (data from observational studies).




Figure 4- Forest plot representing Bell's palsy events in groups of Pfizer/BioNTech recipients vs. Oxford/Astrazeneca recipients (data from observational studies).




Figure 5- Forest plot representing risk ratio Bell's palsy in groups of SARS-CoV-2 infection vs. SARS-CoV-2 vaccine recipients (data from observational studies).




Table 1- Summary of the studies.

		or the studies.				· · · ·
Author, year	Design	Vaccine type doses	vaccinated (% total)	Mean age	Female (%) Vac 6,848 (48%)	Bell's palsy (%) Vac 8 (<0.1%)
El Sahly 2021	RCT	Mod 1 or 2	14,287 (50.2%)	51.3 (18-95) *	Placebo 6,670 (48%)	Placebo 3 (<0.1%)
Codoff 2022	DOT	le 1	24.000/50%	F2 0 (40 + 50) †	Vac 9,828 (44.9%)	Vac 2 (<0.1%)
Sadoff 2022	RCT	Jn 1	21,898(50%)	52.0 (18-100) †	Placebo 9,907 (45.3%)	Placebo 1 (<0.1%)
Thomas 2021	RCT	PfiB 1 or 2	22,026 (50%)	51.0 (16-91) †	Vac 10,704 (48.6%)	Vac 4 (<0.1%)
					Placebo 10,923 (49.6%) Vac 9,575 (44.4%)	Placebo 0 Vac 1 (<0.1%)
Falsey 2021	RCT	OxAz 1 or 2	21,635 (66.66%)	51.0 (18-100) †	Placebo 4,789 (44.4%)	Placebo 0
Voysey 2021	RCT	OxAz 1 or 2	12,082 (50.67%)	NA [‡]	7,045 (60.5%)	Vac 3 (<0.1%)
70,50, 2022	NC1	ON ETGIZ	12,002 (30.0770)		7,043 (00.370)	Placebo 3 (<0.1%)
Barda 2021	cohort	PfiB 1	884,828 (50%)	Vac 38 (27–53) [§]	Vac 423,238 (48%)	Vac 81 (<0.01%)
				Unvac 38 (27–53) §	Unvac 423,238 (48%)	Unvac 59 (<0.01%)
Davidov 2021	cohort	PfiB 1	76 (100%)	64 (49-69) [§]	33 (43.4%)	1 (1.3%)
Filippatos 2021	cohort	PfiB 1 and 2	502 (100%)	48.2 (12.97) #	393 (78.3%)	1 (0.2%)
Tan 2021	cohort	PfiB 1 or 2, Mod 1 or 2	127,081 (100%)	22 (20-30) [§]	4,929 (7.6%)	1 (0.02%)
					Vac 6,424,685 (54%)	Vac 543 (<0.01%)
Klein 2021	cohort	PfiB 1 or 2, Mod 1 or 2	11,845,128 (100%)	49	Unvac NA	Unvac 2379 (0.02%)
Shasha 2022	cohort	PfiB 1 or 2	364,192 (50%)	45.8	Vac 118,525 (51%)	Vac 31 (<0.01%)
					Unvac 111,706 (51%)	Unvac 12 (<0.01%)
McMurry 2021	cohort	PfiB 1 or 2, Mod 1 or 2	68,266(100%)	51.0 (16-91) [§]	31,099 (60.0%)	PfiB 22 (<0.1%) Mod 4 (<0.1%)
						Unvac 75 (0.06%)
	cohort (no BP history)	PfiB 1 or 2	2,594,990 (100%)	46.8 (19.6) #	1,338,032 (51.6%)	284 (<0.1%)
Shibli 2021	cohort (BP History)	PfiB 1 or 2	7,564 (100%)	50.2 (18.7) #	3,388 (44.8%)	14 (<0.1%)
Bardenheier 2021	cohort	PfiB) 1 or 2, Mod 1 or 2	10,356 (48.8%)	NA ¶	13,123 (61.9%)	1 (0.01%)
Koh 2021	cohort	PfiB 1 or 2	1,398,074 (100%)	59 (15–121) [§]	636,124 (45.5%)	11 (2.4%)
Patone 2021	cohort ^Δ	PfiB 1, OxAz 1	34,557,814 (100%)	PfiB 55.9 (20.1) #	PfiB 6,608,730 (57%)	PfiB 250 (<0.01%)
				OxAz 55.1 (14.8) #	OxAz 10,150,568 (52.3%)	OxAz 435 (<0.01%)
Li 2022	cohort ^Δ	OxAz 1 or 2, PfiB 1 or 2, Mod 1 or 2, Jn 1	4,497,003 (96.1%)	47 (36-63) [§]	2,391,109 (51.1%)	247 (<0.1%)
Lai 2022 (adults)	cohort	PfiB 1, CVac 1	335,620 (38%)	PfiB 56.81 (13.43) #	PfiB 80,592 (52.6%)	PfiB 4 (<0.1%)
				CVac 61.58 (11.08) #	CVac 93,561 (51.3%)	CVac 9 (<0.1%)
				Unvac 62.11 (12.85) #	Unvac 318,005 (58.1%)	Unvac 24 (<0.1%)
Hüls 2022	cohort	PfiB 1 or 2, Mod 1 or 2, OxAz 1 or 2, J n	3,696 (94.9%)	27.57 (12.09) #	996 (45.9%)	1 (0.1 %)
11015 2022	CONOTE	FIB 1 01 2, WIOU 1 01 2, OXAZ 1 01 2, 3 11	3,090 (94.970)		990 (43.9%)	
Frontera 2022	$^{\Delta}$	PfiB 1 or 2, Mod 1 or 2, Jn 1	306,907,69(100%)	Vac 50 (35–64) §	63,945,188 (71%) 1st dose 68,569 (49.64%)	1846 (<0.01%)
				PfiB 49 (35–64) §		PfiB 917 (<0.01%)
				Mod 52 (37–66) [§]		Mod 809 (<0.01)
				Jn 44 (31–57) [§]		Jn 117 (<0.01%)
						1st dose 1 (0.00072%)
Lai 2022 (adolescents)	cohort	PfiB 1 or 2	1st dose 138,141 (50.25%)	1 st dose 14.17 (1.82) #		Unvac 3 (0.0021%)
			2 nd dose 119,664 (50.29%)	2 nd dose 14.44 (1.80) #	2 nd dose 58,496 (48.88%)	2 nd dose 4 (0.0033%) Unvac 2 (0.0016%)
Shemer 2021	case-control	PfiB 1 or 2	65 (58.5%)	50.9 (20.2) #	15 (40.5%)	21 (32.3%)
Wan 2022	case-control	PfiB 1 or 2, CVac 1 or 2	126 (8.5%)	PfiB 52.38 (16.35) #	PfiB 6 (37%)	PfiB 14 (5%)
				CVac 56.76 (15.11) #	CVac 9 (32%)	CVac 28 (9%)
El-Shitany 2021	cross-sectional	PfiB 1 or 2	455 (100%)	NA ¶	292 (64.2%)	3 (1.3%)
Noseda 2021	cross-sectional Δ	PfiB 1 or 2, Mod 1 or 2, OxAz 1 or 2, Jn 1 CVac 1 or 2, Convidecia NA	780,073 (100%)	54 (42–68) [§] ,	566,179 (72.58%)	3,320 (0.42%)
Tamaki 2021	cross-sectional	NA NA	63,551 (50%)	NA	NA	NA
Walker 2022 [♦]	sccs	Mod 1	255,446 (100%)	34 (27–45) [§]	36 (46%)	78 (0.03%)
Ab Rahman 2022	sccs	PfiB 1 or 2, CVac 1 or 2, OxAz 1 or 2	35,201,509 (100%)	50.1 (15.2) #	10,282,321 (50.9%)	PfiB 27 (<0.1%)
						OxAz 5 (<0.1%)
						CVac 21 (<0.1%)

CVac: CoronaVac, IQR: interquartile range, Jn: Janssen, Mod: Moderna, NA: not available, OxAz: Oxford/AstraZeneca, PfiB, Pfizer/BioNTech, RCT: randomized controlled trial, SCCS: self-controlled case series, SD standard deviation, Vac: Vaccinated, Unvac: Unvaccinated. For case reports and case series, please refer to the supplementary Table S9.

- * Mean (range)
- † Median (range)
- [‡] varied between the included trials- the majority between 18-55
- § Median (IQR)
- | Only in individuals reporting Bell's palsy
- ¶ El-Shitany 2021, number of subject with age <60y: 299 (65.7%); ≥60y: 156 (34.3%); Bardenheier 2021, number of subjects with age 65-74y: 4981 (23.5%); 75-84y: 5912 (27.9%); ≥85y: 6328 (29.8%)
- # Mean (SD)
- ^a Noseda 2021: Data from the VigiBase database accessed as of May 16, 2021; Patone 2021: data from the English National Immunisation (NIMS) database; Frontera 2022: data from the VAERS accessed between January 1, 2021, and June 14, 2021; Li 2022: data from the SIDIAP database.
- ^o This study also included individuals receiving Oxford/AstraZeneca but overlapped with other studies.